

Clinical Practice Pearls: Managing Patients With Major Depressive Disorder Showing an Inadequate Response to First-Line Therapies

Resource	Address
Adler DA, Possemato K, Mavandadi S, et al. Psychiatric status and work performance of veterans of Operations Enduring Freedom and Iraqi Freedom. <i>Psychiatr Serv</i> . 2011;62:39-46.	https://pubmed.ncbi.nlm.nih.gov/21209298/
American Psychiatric Association (APA). Treating Major Depressive Disorder: A Quick Reference Guide. 2010.	https://psychiatryonline.org/pb/assets/raw/sitewide/practice_guidelines/guidelines/mdd-guide.pdf
Bennabi D, Haffen E, Van Waes V. Vortioxetine for cognitive enhancement in major depression: From animal models to clinical research. <i>Front Psychiatry</i> . 2019;10:771.	https://pubmed.ncbi.nlm.nih.gov/31780961/
Blore JD, Sim MR, Forbes AB, Creamer MC, Kelsall HL. Depression in Gulf War veterans: A systematic review and meta-analysis. <i>Psychol Med</i> . 2015;45:1565-1580.	https://pubmed.ncbi.nlm.nih.gov/25697603/
Bolling MY, Kohlenberg RJ. Reasons for quitting serotonin reuptake inhibitor therapy: Paradoxical psychological side effects and patient satisfaction. <i>Psychother Psychosom</i> . 2004;73:380-385.	https://pubmed.ncbi.nlm.nih.gov/15479994/
Cartwright C, Gibson K, Read J, Cowan O, Dehar T. Long-term antidepressant use: Patient perspectives of benefits and adverse effects. <i>Patient Prefer Adherence</i> . 2016;10:1401-1407.	https://pubmed.ncbi.nlm.nih.gov/27528803/
Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: A systematic review and network meta-analysis. <i>Lancet</i> . 2018;391:1357-1366.	https://pubmed.ncbi.nlm.nih.gov/29477251/
Clayton AH, Alkis AR, Parikh NB, Votta JG. Sexual dysfunction due to psychotropic medications. <i>Psychiatr Clin N Am</i> . 2016;39:427-463.	https://pubmed.ncbi.nlm.nih.gov/27514298/
Conradi HJ, de Jonge P. Presence of individual (residual) symptoms during depressive episodes and periods of remission: A 3-year prospective study. <i>Psychol Med</i> . 2011;41:1165-1174.	https://pubmed.ncbi.nlm.nih.gov/20932356/
DeBeer BB, Kimbrel NA, Meyer EC, Gulliver SB, Morissette SB. Combined PTSD and depressive symptoms interact with post-deployment social support to predict suicidal ideation in Operation Enduring Freedom and Operation Iraqi Freedom veterans. <i>Psychiatry Res</i> . 2014;216:357-362.	https://pubmed.ncbi.nlm.nih.gov/24612971/
Fagiolini A, Florea I, Loft H, Christensen MC. Effectiveness of vortioxetine on emotional blunting in patients with major depressive disorder with inadequate response to SSRI/SNRI treatment. <i>J Affect Disord</i> . 2021;283:472-479.	https://pubmed.ncbi.nlm.nih.gov/33516560/

<p>Fava M, Rush AJ, Wisniewski SR, et al. A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: A STAR*D report. <i>Am J Psychiatry</i>. 2006;163:1161-1172.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/16816220/</p>
<p>Ferguson JM. SSRI Antidepressant medications: Adverse effects and tolerability. <i>Prim Care Companion J Clin Psychiatry</i>. 2001;3:22-27.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/15014625/</p>
<p>Goodwin GM, Price J, De Bodinat C, Laredo J. Emotional blunting with antidepressant treatments: A survey among depressed patients. <i>J Affect Disord</i>. 2017;221:31-35.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/28628765/</p>
<p>Hutka P, Krivosova M, Muchova Z, et al. Association of sleep architecture and physiology with depressive disorder and antidepressants treatment. <i>Int J Mol Sci</i>. 2021;22:1333.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/33572767/</p>
<p>Ishak WW, Greenberg JM, Cohen RM. Predicting relapse in major depressive disorder using patient-reported outcomes of depressive symptom severity, functioning, and quality of life in the Individual Burden of Illness Index for Depression (IBI-D). <i>J Affect Disord</i>. 2013;151:59-65.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/23790554/</p>
<p>Jacobsen, Zhong W, Nomikos G, Clayton A. Paroxetine, but not vortioxetine, impairs sexual functioning compared with placebo in healthy adults: A randomized, controlled trial. <i>J Sex Med</i>. 2019;16:1638-1649.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/31405765/</p>
<p>Jakupcak M, Cook J, Imel Z, Fontana A, Rosenheck R, McFall M. Posttraumatic stress disorder as a risk factor for suicidal ideation in Iraq and Afghanistan War veterans. <i>J Trauma Stress</i>. 2009;22:303-306.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/19626682/</p>
<p>Katona C, Hansen T, Olsen CK. A randomized, double-blind, placebo-controlled, duloxetine-referenced, fixed-dose study comparing the efficacy and safety of Lu AA21004 in elderly patients with major depressive disorder. <i>Int Clin Psychopharmacol</i>. 2012;27:215-223.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/22572889/</p>
<p>Kroenke K, Spitzer RL, Williams JB. The PHQ-9: Validity of a brief depression severity measure. <i>J Gen Intern Med</i>. 2001;16:606-613.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/11556941/</p>
<p>Lam RW, Michalak EE, Bond DJ, Tam EM, Axler A, Yatham LN. Which depressive symptoms and medication side effects are perceived by patients as interfering most with occupational functioning? <i>Depress Res Treat</i>. 2012;2012:630206.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/22611491/</p>
<p>Lam RW, Michalak EE, Bond DJ, Tam EM, Axler A, Yatham LN. Which depressive symptoms and medication side effects are perceived by patients as interfering most with occupational functioning? <i>Depress Res Treat</i>. 2012;2012:630206.</p>	<p>https://pubmed.ncbi.nlm.nih.gov/22611491/</p>

Liguori C, Ferini-Strambi L, Izzi F, et al. Preliminary evidence that vortioxetine may improve sleep quality in depressed patients with insomnia: A retrospective questionnaire analysis. <i>Br J Clin Pharmacol</i> . 2019;85:240-244.	https://pubmed.ncbi.nlm.nih.gov/30328132/
Maguen S, Cohen B, Cohen G, Madden E, Bertenthal D, Seal K. Gender differences in health service utilization among Iraq and Afghanistan veterans with posttraumatic stress disorder. <i>J Womens Health (Larchmt)</i> . 2012;21(6):666-673.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3366102/
Maguen S, Ren L, Bosch JO, Marmar CR, Seal KH. Gender differences in mental health diagnoses among Iraq and Afghanistan veterans enrolled in veterans affairs health care. <i>Am J Public Health</i> . 2010;100:2450-2456.	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2978175/
McClintock SM, Husain MM, Wisniewski SR, et al. Residual symptoms in depressed outpatients who respond by 50% but do not remit to antidepressant medication. <i>J Clin Psychopharmacol</i> . 2011;31:180-186.	https://pubmed.ncbi.nlm.nih.gov/21346613/
McGrath PJ, Stewart JW, Fava M, et al. Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: A STAR*D report. <i>Am J Psychiatry</i> . 2006;163:1531-1541.	https://pubmed.ncbi.nlm.nih.gov/16946177/
McIntyre RS, Lophaven S, Olsen CK. A randomized, double-blind, placebo-controlled study of vortioxetine on cognitive function in depressed adults. <i>Int J Neuropsychopharmacol</i> . 2014;17:1557-1567.	https://pubmed.ncbi.nlm.nih.gov/24787143/
Morris DW, Trivedi MH. Measurement-based care for unipolar depression. <i>Curr Psychiatry Rep</i> . 2011;13:446-458.	https://pubmed.ncbi.nlm.nih.gov/21935633/
Mouret J, Lemoine P, Minuit MP, Benkelfat C, Renardet M. Effects of trazodone on the sleep of depressed subjects--a polygraphic study. <i>Psychopharmacology</i> . 1988;95(suppl):S37-S43.	https://pubmed.ncbi.nlm.nih.gov/3133713/
National Institute of Mental Health (NIMH). Major Depression. Updated January 2022.	https://www.nimh.nih.gov/health/statistics/major-depression
Nierenberg AA, Fava M, Trivedi MH, et al. A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: A STAR*D report. <i>Am J Psychiatry</i> . 2006;163:1519-1530.	https://pubmed.ncbi.nlm.nih.gov/16946176/
Niernberg AA, Loft H, Olsen CK. Treatment effects on residual cognitive symptoms among partially or fully remitted patients with major depressive disorder: A randomized, double-blinded, exploratory study with vortioxetine. <i>J Affect Disord</i> . 2019;250:35-42.	https://pubmed.ncbi.nlm.nih.gov/30826492/
Oluboka OJ, Katzman MA, Habert J, et al. Functional recovery in major depressive disorder: Providing early optimal treatment for the individual patient. <i>Int J Neuropsychopharmacol</i> . 2018;21:128-144.	https://pubmed.ncbi.nlm.nih.gov/29024974/

Park LT, Zarate CA Jr. Depression in the primary care setting. Reply. <i>N Engl J Med</i> . 2019;380:2279-2280.	https://pubmed.ncbi.nlm.nih.gov/31167073/
Petersen T, Papakostas GI, Posternak MA, et al. Empirical testing of two models for staging antidepressant treatment resistance. <i>J Clin Psychopharmacol</i> . 2005;25:336-341.	https://pubmed.ncbi.nlm.nih.gov/16012276/
Price J, Cole V, Goodwin GM. Emotional side-effects of selective serotonin reuptake inhibitors: Qualitative study. <i>Br J Psychiatry</i> . 2009;195:211-217.	https://pubmed.ncbi.nlm.nih.gov/19721109/
Ramsawh HJ, Fullerton CS, Herberman Mash HB, et al. Risk for suicidal behaviors associated with PTSD, depression, and their comorbidity in the U.S. Army. <i>J Affect Disord</i> . 2014;161:116-122.	https://pubmed.ncbi.nlm.nih.gov/24751318/
Read J, Cartwright C, Gibson K. Adverse emotional and interpersonal effects reported by 1829 New Zealanders while taking antidepressants. <i>Psychiatry Res</i> . 2014;216:67-73.	https://pubmed.ncbi.nlm.nih.gov/24534123/
Read J, Williams J. Adverse effects of antidepressants reported by a large international cohort: Emotional blunting, suicidality, and withdrawal effects. <i>Curr Drug Saf</i> . 2018;13:176-186.	https://pubmed.ncbi.nlm.nih.gov/29866014/
Rosenblat JD, Simon GE, Sachs GS, et al. Treatment effectiveness and tolerability outcomes that are most important to individuals with bipolar and unipolar depression. <i>J Affect Disord</i> . 2019;243:116-120.	https://pubmed.ncbi.nlm.nih.gov/30241026/
Rossum RC, Shortreed S, Coleman KJ, et al. Antidepressant adherence across diverse populations and healthcare settings. <i>Depress Anxiety</i> . 2016;33:765-774.	https://pubmed.ncbi.nlm.nih.gov/27320786/
Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: A STAR*D report. <i>Am J Psychiatry</i> . 2006;163:1905-1917.	https://pubmed.ncbi.nlm.nih.gov/17074942/
Rush AJ, Trivedi MH, Wisniewski SR, et al. Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depression. <i>N Engl J Med</i> . 2006;354:1231-1242.	https://pubmed.ncbi.nlm.nih.gov/16554525/
Rzepa E, Dean Z, McCabe C. Bupropion administration increases resting-state functional connectivity in dorso-medial prefrontal cortex. <i>Int J Neuropsychopharmacol</i> . 2017;20:455-462.	https://pubmed.ncbi.nlm.nih.gov/28340244/
Schittecatte M, Dumont F, Machowski R, Cornil C, Lavergne F, Wilmotte J. Effects of mirtazapine on sleep polygraphic variables in major depression. <i>Neuropsychobiology</i> . 2002;46:197-201.	https://pubmed.ncbi.nlm.nih.gov/12566938/
Solmi M, Miola A, Croatto G, et al. How can we improve antidepressant adherence in the management of depression? A targeted review and 10 clinical recommendations. <i>Braz J Psychiatry</i> . 2020;43:189-202.	https://pubmed.ncbi.nlm.nih.gov/32491040/

Spitzer RL, et al. GAD-7 Anxiety.	https://adaa.org/sites/default/files/GAD-7 Anxiety- updated_0.pdf
Spitzer RL, Kroenke K, Williams JBW, Lowe B. A brief measure for assessing generalized anxiety disorder: The GAD-7. <i>Arch Intern Med.</i> 2006;166:1092-1097.	https://pubmed.ncbi.nlm.nih.gov/16717171/
Taylor RW, Marwood L, Oprea E, et al. Pharmacological augmentation in unipolar depression: A guide to the guidelines. <i>Int J Neuropsychopharmacol.</i> 2020;23:587-625.	https://pubmed.ncbi.nlm.nih.gov/32402075/
Thase ME, Friedman ES, Biggs MM, et al. Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: A STAR*D report. <i>Am J Psychiatry.</i> 2007;164:739-752.	https://pubmed.ncbi.nlm.nih.gov/17475733/
Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. <i>N Engl J Med.</i> 2006;354:1243-1252.	https://pubmed.ncbi.nlm.nih.gov/16554526/
Trivedi MH, Rush AJ, Crismon ML, et al. Clinical results for patients with major depressive disorder in the Texas Medication Algorithm Project. <i>Arch Gen Psychiatry.</i> 2004;61:669-680.	https://pubmed.ncbi.nlm.nih.gov/15237079/
Trivedi MH, Rush AJ, Wisniewski SR, et al. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: Implications for clinical practice. <i>Am J Psychiatry.</i> 2006;163:28-40.	https://pubmed.ncbi.nlm.nih.gov/16390886/
Turner EH, Matthews AM, Linardatos E, Tell RA, Rosenthal R. Selective publication of antidepressant trials and its influence on apparent efficacy. <i>N Engl J Med.</i> 2008;358:252-260.	https://pubmed.ncbi.nlm.nih.gov/18199864/
US Department of Veterans Affairs. 2022 National Veteran Suicide Prevention Report. September 2022.	https://www.mentalhealth.va.gov/docs/data- sheets/2022/2022-National-Veteran-Suicide- Prevention-Annual-Report-FINAL-508.pdf
US Department of Veterans Affairs. Suicide Among Veterans and Other Americans 2001-2014. August 3, 2016.	https://www.mentalhealth.va.gov/docs/2016suicid edatareport.pdf

All URLs accessed June 4, 2023